A study on the price of generic drugs of Brigatinib in Bangladesh

Brigatinib (Brigatinib), a targeted drug, was developed specifically for the treatment of ALK (anaplastic lymphoma kinase) gene mutation-positive non-small cell lung cancer (NSCLC). As a tyrosine kinase inhibitor (TKI), Brigatinib (Brigatinib) can precisely target the abnormal kinase caused by ALK mutation, and effectively curb the growth and spread of tumor cells by inhibiting its activity.

Brigatinib has a unique mechanism of action. It can bind tightly to ALK kinase, thereby blocking its phosphorylation activity and further interfering with the growth signaling pathways of cancer cells. This drug is particularly suitable for patients with ALK mutation-positive non-small cell lung cancer, especially those who are resistant to first-generation ALK inhibitors (such as crizotinib). At the same time, Brigatinib (Brigatinib) has shown significant therapeutic effects against certain common ALK mutant forms, such as G1202R . In addition, it also has a certain inhibitory effect on ROS1kinase, indicating that Brigatinib may also play an important role in the treatment of certain tumors related to ROS1 mutations.

Mentioning price, China'sBrigatinib branded drug sells for about four to five thousand yuan per box. However, actual prices may be affected by region, pharmacy, and health insurance reimbursement policies.

Generic drugs offer a more economical alternative to brand-name drugs in some countries and regions. Taking Bangladesh as an example, the price of generic drugs of brigatinib is about more than 2,000 yuan per box. Although the price is still higher than that in some regions, it has been significantly reduced compared with brand-name drugs. These generic drugs are basically the same in ingredients as brand-name drugs, but are more affordable. When patients choose generic drugs, they must ensure that the drugs are from regular sources to ensure the quality and therapeutic effect of the drugs.

In summary, brigatinib is an effective targeted drug for ALKNew treatment hope for patients with mutation-positive non-small cell lung cancer. Although their brand-name counterparts are more expensive, the emergence of generic drugs offers patients a more economical treatment option.